It sounds like Merck may have partnered up with the wrong company. There seems to be a lot of that going around. It's hard to believe that the larger companies don't grasp the capabilities of Leronlimab's mechanism of action. Or, maybe they do. It seems like every day, the larger companies are just trying different poisons. It will be nice, for us to get our first approval.